An Expert View looking at the key factors that will drive deal activity over the next year from Michael Jewell, partner, head of healthcare & life sciences at Cavendish Corporate Finance.
Last year was an extraordinary period for consolidation in the pharmaceutical industry, with mergers and acquisitions (M&A) deals globally reaching $265 billion, a more than 25% surge on 2017.
As big pharma looks to increase pipelines of innovative and orphan drugs, particularly in the biopharma sub-sector, mega deals dominated the scene.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze